Consistent with previous data showing upregulated SGLT2 expression in several cancer models and its association to metastasis, drug resistance, poor prognosis and survival, here, we found increased SGLT2 mRNA and protein levels in CRC cells compared to non-tumor cells [3–7]. The gene discussed is SLC5A2; the disease is colorectal carcinoma.